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COMMENTARIES
Biomedical Research Involving Prisoners
Ethical Values and Legal Regulation
Lawrence O. Gostin, JD
UNTIL THE EARLY 1970S, R. J. REYNOLDS, DOWChemical, the US Army, major pharmaceuticalcompanies, and other sponsors conducted a widevariety of research on prisoners—a captive, vul-
nerable, and easily accessible population.1,2 During that time,
approximately 90% of all pharmaceutical research was con-
ducted on prisoners, who also were subjected to biochemi-
cal research ranging from testing diet drinks and simple de-
tergents to studies involving dioxin and chemical warfare
agents.3 From 1962 to 1966, for example, 33 pharmaceuti-
cal companies tested 153 experimental drugs at Holmes-
burg Prison in Philadelphia, including a Retin-A (treti-
noin) study in which researchers did not seek informed
consent and prisoners were not adequately treated for pain.4
By the mid-1970s, biomedical research in prisons sharply
declined as knowledge of the exploitation of prisoners be-
gan to emerge and the National Commission for the Pro-
tection of Human Subjects of Biomedical and Behavioral Re-
search was formed.5
Federal regulations to protect human subjects of re-
search were established in 1974 and modified and codified
in 1981.6 The regulations were revised in 1991 as the Fed-
eral Policy for the Protection of Human Subjects and be-
came known as the Common Rule. The Common Rule ap-
plies to research funded by the Department of Health and
Human Services (DHHS); to private institutions that un-
dertake a Federal-Wide Assurance of Compliance; and, with
broad exceptions, to 16 additional federal agencies.6 The US
Food and Drug Administration has similar regulations for
research involving the products it regulates. The Common
Rule contains requirements for institutional review board
(IRB) review, informed consent, and risk/benefit analysis.
These regulations also provide extra protections for par-
ticularly vulnerable populations: pregnant women, fe-
tuses, and neonates (subpart B); prisoners (subpart C); and
children (subpart D). Subpart C, promulgated in 1978 in
response to recommendations from the national commis-
sion,7 strictly limits research involving prisoners. How-
ever, federal agencies (except for the DHHS, Central Intel-
ligence Agency, and Social Security Administration) have
not adopted subpart C, perhaps because it is so restrictive.
In 1981, Food and Drug Administration regulations spe-
cifically applicable to prisoners were blocked by a lawsuit
brought by prisoners wishing to participate in research.8 In
1997, the Bureau of Prisons adopted its own additional regu-
lations for research involving prisoners in federal custody.9
Under subpart C, research on prisoners must present no
more than minimal risk, defined as the risk of harm nor-
mally encountered in their daily lives or in the routinemedi-
cal, dental, or psychological examination of healthy per-
sons. Subpart C identifies 4 categories of permitted research
relating to (1) possible causes, effects, and processes of in-
carceration; (2) prisons as institutional structures or pris-
oners as incarcerated persons; (3) conditions particularly
affecting prisoners as a class; and (4) practices that have the
intent and reasonable probability of improving the health
or well-being of research participants. Categories 3 and 4
may proceed only after the Secretary of Health and Human
Services has consulted with experts and published a Fed-
eral Register notice of the intent to approve. A fifth cat-
egory of research was permitted when subpart C was
amended in 2003 to allow epidemiologic research on speci-
fied diseases in which prisoners are included in the popu-
lation of interest but are not the sole study group. In such a
case, the IRB must determine that the epidemiologic re-
search involves minimal risk or no more than inconve-
nience to prisoner-subjects.10
The definition of minimal risks is so narrow and confus-
ing (eg, are the risks to be measured in terms of threats en-
countered in life on the outside, or within prison?), and the
secretarial review is so onerous (taking months or years to
review), that research subject to subpart C is often avoided.1
Because these regulations apply only to a few federal agen-
cies and institutions that voluntarily comply with them
through a Federal-Wide Assurance of Compliance, the ma-
jority of prison research is conducted outside the purview
of subpart C. Federal oversight of research in prisons, there-
fore, is either too restrictive (effectively impeding respon-
sible research) or inapplicable (opening the door to exploi-
tation or abuse). It is in this context that the DHHS asked
the Institute of Medicine (IOM) to consider the need for de-
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veloping a new ethical framework for prisoner research and
to identify regulatory safeguards.1
The Correctional Environment
and Prisoner Research
The US correctional system has undergone major changes
since the adoption of federal regulations. The overall cor-
rectional population (including persons in prison or jail and
on parole or probation) has increased 5-fold between 1978
and 2005, to nearly 7million people.11 The US currently has
the world’s largest incarcerated population and highest in-
carceration rate, accounting for one quarter of the world’s
prison population.12 Correctional facilities are often over-
crowded and many inmates have limited access to pro-
grams, services, and health care.13 Despite prisoners’ con-
stitutional right to humanemedical care, several large prison
systems have been placed under judicial supervision due to
inadequate treatment.14 The percentage of disadvantaged in-
dividuals under correctional supervision is increasing, in-
cluding racial minorities, women, and children. For ex-
ample, in 2005, nearly 12% of US black males aged 25 to
29 years were incarcerated, and 60% of offenders in local
jails were racial or ethnic minorities.11 A high proportion
of inmates have communicable (human immunodefi-
ciency virus [HIV]/AIDS, hepatitisC, tuberculosis) or chronic
(mental illness, diabetes) diseases, drug or alcohol depen-
dency, and low literacy.15
Prisoners are vulnerable to exploitation not only because
of their low socioeconomic status and poor health but also
because of their restricted autonomy and liberty. Highly
vulnerable, often poorly educated prisoners may not be
able to give informed consent or have a reasonable expecta-
tion of privacy within closed prison settings. In this
research environment, prisoners may not be able to mean-
ingfully choose between research participation and nonpar-
ticipation.
Toward a System for Ethical Research
Involving Prisoners
Finding a balance between encouraging beneficial re-
search and safeguarding prisoners is challenging and po-
litically controversial. The history of prisoner exploitation
cautions against allowing research. However, modern sci-
ence might be able to improve understanding of the intrac-
table problems faced by prisoners, including the treatment
of substance abuse and mental illness, and the effective-
ness of programs designed to help prisoners make a suc-
cessful transition to the community. Such research is im-
portant, not only to prisoners but also to the broader
community, especially because approximately 95% of pris-
oners will eventually be released from prison.11 However, a
comprehensive and stringent continuumof safeguards is re-
quired to protect this vulnerable population against abuse.
The following proposalswould provide such a systemof safe-
guards while allowing responsible research.
Expand the Definition of Prisoner. Subpart C currently
defines a prisoner as any person who is “involuntarily con-
fined or detained in a penal institution”; detained in a fa-
cility as an alternative to prosecution or incarceration; or
detained pending arraignment, trial, or sentencing. The em-
phasis on custodial detention, however, is too narrow.With
the advent of “alternatives” to incarceration (including house
arrest, day reporting centers, and halfway houses), the ex-
isting definition extends the protections of subpart C to only
2.1 million of the nearly 7 million persons under adult cor-
rectional supervision.1 This leaves nearly 5 million people
who lack the protections of the regulations. To ensure pro-
tection for this vulnerable group, a newdefinition of the term
“prisoner” should comprehensively cover all individuals
whose autonomy and liberty are restricted by the justice
system.
Ensure Universal, Consistent Ethical Protection. Pris-
oner research regulations offer a patchwork of protection,
ranging from no safeguards at all (for research not funded
by a Common Rule agency), to basic Common Rule over-
sight, to heightened, overlapping, or possibly inconsistent
regulations. Instead, all research onprisoners should be regu-
lated uniformly, irrespective of the source of funding, sup-
porting agency, or type of correctional facility. There is no
ethical justification for lower levels of protection for pris-
oners simply because the funder is not a Common Rule
agency or is a private corporation.
Create a National Database of Prisoner Research. Be-
causemost prisoner research is currently unregulated, there
is no reliable basis to know how many studies have been
undertaken, what safeguards have been used, and what has
been learned as a result of the research. Consequently, the
DHHS or another appropriate agency should create a pub-
licly accessible national prison research registry. The reg-
istry would permit greater accountability, provide a scien-
tific method for assessing the success of research projects,
and facilitate the implementation of beneficial research find-
ings to prisoner populations. By creating a national regis-
try and uniformly regulating all prisoner studies, therewould
also be greater transparency and public accountability.
Shift From a Category-Based to a Risk-Benefit Ap-
proach to Research Review. The categories of permissible
research established under subpart C do not provide con-
sistent, reliable, or sufficient protection for prisoner re-
search. Investigators and IRBs have difficulty placing re-
search protocols into particular categories, and the structure
does not focus attention on the conditions of confinement
or the precise risks and benefits of the particular research
protocol, which are the key ethical factors. Instead, a risk-
benefit approach that provides a continuum of protections
depending on the stringency of the correctional setting (simi-
lar to subpart D for children) is a more practical approach
to ensuring safe and ethical prisoner research. Under this
framework, research with prisoners should be conducted
only if it offers a distinctly favorable benefit-to-risk ratio,
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not because prisoners are a convenient source of research
participants or have no access to therapeutic treatment.
Update the Ethical Framework to Include Collabora-
tive Responsibility. The National Commission viewed re-
spect for persons and justice as the 2 principal values that
should guide research. However, collaborative responsibil-
ity is also important, meaning that to the extent possible,
stakeholders (eg, prisoners, correctional officers, medical
staff) should participate in the design, planning, and imple-
mentation of research. Participation helps ensure that all rel-
evant groups have a stake in ensuring responsible re-
search. A collaborative, cooperative approach to human
subjects research is also likely to clarify the study’s meth-
ods and objectives, enhance the process of securing mean-
ingful informed consent, andmaximize the likelihood of us-
able scientific knowledge flowing from the research.
Enhance SystematicOversight of Research.Current over-
sight of prisoner research, where it takes place at all, is ef-
fectively limited to IRB review, which has been criticized
as highly variable.16 Instead, safeguards should be strength-
ened, made consistent, and applied in relation to the levels
of risk and restriction of liberty experienced by prisoner-
subjects. A prison research participant advocate, who is fa-
miliar with the local correctional setting but not an em-
ployee of the facility, should monitor the ethical conduct
of the study. This advocate would provide more systematic
and ongoing safeguards for prisoners.
Should Research Be Permitted in Prisons?
The proposals in the IOM report on research involving pris-
oners were intensely controversial, with some prisoner ad-
vocates decrying what they saw as a relaxation of existing
safeguards17 and investigators complaining that the pro-
posed new rules are overly restrictive.18 Certainly, the pre-
requisites for ethical research—informed consent and pri-
vacy—are difficult to ensure in many correctional settings.
The prison environment, moreover, is rarely conducive to
ethical research: overcrowded, inherently coercive, secre-
tive, and unaccountable. The poor quality of some prison
health care systems is also a major concern because in-
mates may volunteer for research simply to gain access to
basic medical care, and prisoners may not receive effective
treatment for harms that occur during the research study.
Consequently, critics assert that only research posingmini-
mal risk should be permissible.17
Although these are valid concerns, human subject re-
search not only imposes risks and burdens but can also con-
fer benefits. Modern advocacy movements have called for
greater, not less, access to clinical trials by women, persons
living with HIV/AIDS, and patients with cancer.19 Epide-
miologic, sociological, psychological, and biomedical re-
searchmight be able to improve the health of prisoners and
their living conditions. The opening of otherwise closed in-
stitutions to outside health professionals also could in-
crease transparency and public accountability. Research can
help society better understand how to improve prisoners’
chances to succeed. This is an especially worthy endeavor,
with 600000prisoners reentering the community each year.20
Much of the controversy surrounding the IOM’s propos-
als concerned biomedical research, which carries the great-
est risks. The IOM recommended particularly strict safe-
guards for biomedical research.1 Such research should be
limited to phase 3 trials that offer potential benefits to the
research participants and not simply to prisoners as a class
or the public at large. Further, the ratio of prisoner to non-
prisoner study participants should not exceed 50%, to en-
sure a fair distribution of research burdens.With a high pro-
portion of nonprisoner participants, the potential for prisoner
abuse will be substantially reduced. In addition, research
should not take place in institutions that cannot ensure
prompt access to adequate medical services. These addi-
tional safeguards could lead to beneficial research, helping
to find answers to the most intractable problems in insti-
tutions, such as HIV/AIDS, hepatitis C, tuberculosis, men-
tal illness, and substance abuse.
The IOM report1 recounted the painful history of medi-
cal mistreatment in the Tuskegee syphilis trials and Holm-
esburg prison, as well as prisoner abuse at Guanta´namo Bay
and Abu Ghraib. It reawoke debates stemming from as far
back as the Nuremberg Code, which requires that human
subjects have “the capacity to give consent . . . [and] be able
to exercise free power of choice, without . . . constraint or
coercion.”21 The ethical issues are of great importance be-
cause, as Dostoyevsky observed, “The degree of civiliza-
tion in a society can be judged by entering its prisons.”22
But near-absolute prohibitions on research based on the sor-
did history of exploitation would leave prisoners without
the benefits of modern science that could improve the qual-
ity of their lives and conditions unique to prisons.With sys-
tematic oversight, humandignity and scientific progress need
not be incompatible.
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Pay-for-Performance
Will the Latest Payment Trend Improve Care?
Meredith B. Rosenthal, PhD
R. Adams Dudley, MD, MBA
PAY-FOR-PERFORMANCE PROGRAMSARENOWFIRMLY EN-sconced in the payment systems of US public andprivate insurers across the spectrum.More than halfof commercial healthmaintenance organizations are
using pay-for-performance, and recent legislation requires
Centers for Medicare & Medicaid Services (CMS) to adopt
this approach for Medicare.1 As commercial programs have
evolved during the last 5 years, the categories of providers
(clinicians, hospitals, and other health care facilities), num-
bers of measures, and dollar amounts at risk have in-
creased. In addition, acceptance of performance measure-
ment among physicians and organized medicine has
broadened, with the American Medical Association com-
mitting to the US Congress in February 2006 that it would
develop more than 100 performance measures by the end
of 2006.2
To date, widespread experimentation has yielded impor-
tant lessons and highlighted critical challenges to paying for
performance. Several recently published evaluations have
demonstrated both the potential of pay-for-performance and
the need for careful design of programs to ensure their ef-
fectiveness.3,4 Despite purchasers’ enthusiasm for pay-for-
performance, it has become clear that it should not be a fore-
gone conclusion that these programs will benefit patients
or even significantly assist providers who want to improve
care.4,5
While recognizing the shortcomings of current pay-for-
performance programs, it is critical to reaffirm what most
physicians and health care purchasers alike believe: the cur-
rent payment system thwarts high-quality care and needs
to be reformed. Furthermore, the basic intent of pay-for-
performance—to encourage and assist providers in offer-
ing the most clinically appropriate care—would be a posi-
tive step from the current payment system.Nonetheless, there
are many details about how pay-for-performance would ac-
tually be implemented that could mitigate or even reverse
some of its good intent.
Our objective is to review dimensions of pay-for-
performance programs that economic theory or available data
suggest would be important determinants of their influ-
ence. With CMS poised to enter the fray and many com-
mercial payers evaluating, expanding, and updating their
first-generation pay-for-performance programs, the time is
right to examine critically the various approaches to pay-
for-performance.
Five Key Design Elements
of Pay-for-Performance
Purchasers must make many decisions when implementing
pay-for-performance programs.6 Based on our experience
studying incentive programs,4,5,7-9 5 aspects of program de-
sign that are likely to be most consequential have been iden-
tified. These 5 dimensions govern the types of provider be-
havior being influenced and the degree to which incentives
are felt by clinicians. The TABLE presents the options avail-
able for each of these dimensions and includes examples of
empirical or theoretical literature addressing the rationale for
and against each option, as well as what is known about cur-
rently operating pay-for-performance programs. In discuss-
ing targets of pay-for-performance, the term provider is used
to refer collectively to physicians, hospitals, and any other cli-
nician or clinical entity that can bill for services.
Pay-for-Performance as Individual vs GroupMotivator.
In markets in which there are larger medical groups, phy-
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